- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04290988
Circuitry Assessment and Reinforcement Training Effects on Recovery (CARTER)
Circuitry Assessment and Reinforcement Training Effects on Recovery (CARTER)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Neurofeedback, a form of biofeedback, provides a visual and/or audio representation of an individual's neural electrical activity from live EEG recording. Using operant conditioning principles, individuals are trained to increase or reduce patterns of brainwave activity to modify behavior and performance. Although neurofeedback has not yet been investigated as a treatment for aphasia or other communication deficits due to stroke or neurodegenerative disease, it may be effective. Previous studies have observed improvement in cognitive and behavioral measures in those with conditions such as Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder. Furthermore, it has been associated with reduced anxiety and sleep disruption, which both exacerbate language and communication impairments. Research is needed to determine if neurofeedback may be an effective treatment for language disorders such as PPA and post-stroke communication disorders.
It is possible that EEG neurofeedback, which focuses on improving abnormal brainwave patterns, could provide certain therapeutic benefits to individuals with PPA or post-stroke aphasia, either by directly affecting neural networks that underlie language, or more generally by reducing anxiety and inattention through behavioral conditioning. Reduction of anxiety in neurological diseases can be beneficial not only for functional performance but also sleep duration and quality.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of PPA or aphasia secondary to stroke and presence of naming deficits with confirmation of diagnosis by neurologist
- Capable of giving informed consent or indicating another to provide informed consent
- Age 18 or older.
- If aphasia is secondary to stroke, the stroke must have occurred between 6 months and 5 years prior to enrollment in the study.
Exclusion Criteria:
- Lack of English proficiency
- Not medically stable
- Picture naming accuracy above 80% on the Philadelphia Naming Test (PNT)
- Prior history of neurologic disease affecting the brain (e.g., brain tumor, multiple sclerosis, traumatic brain injury) other than stroke or PPA and its underlying neurological pathologies: Alzheimer's Disease, Frontotemporal Lobar Degeneration or Dementia with Lewy bodies
- Prior history of severe psychiatric illness, developmental disorders or intellectual disability (e.g., PTSD, major depression, bipolar disorder, schizophrenia, obsessive compulsive disorder (OCD), autism spectrum disorders)
- Uncorrected severe visual loss or hearing loss by self-report and medical records
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Active EEG Neurofeedback
15 sessions of active EEG neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
|
Active EEG neurofeedback
|
Sham Comparator: Sham Feedback
15 sessions of sham neurofeedback at a frequency of 3-5 sessions per week for a duration of 3-5 weeks.
|
Sham EEG feedback sessions identical to active sessions except that the feedback given to the participant will not be based on the individual's live EEG activity.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Number of content units expressed in the Picture Description Test
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in Number of content units expressed by the participant when describing what is seen in a picture.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in number of items correctly named on the Philadelphia Naming Test
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in number of items correctly named on a behavioral picture naming assessment.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in Controlled Oral Word Association test (COWA) score
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
This is a measure of attention, executive function, and word-retrieval.
COWA scores range from 0 to infinity.
Lower scores represent more language impairment.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in quality of sleep as assessed by the Pittsburgh Sleep Quality Index (PSQI)
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in quality of sleep measured with The Pittsburgh Sleep Quality Index (PSQI).
This has 7 items with each item scored from 0 to 3. Overall score ranges from 0 to 21 with higher scores representing poor sleep quality.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in anxiety as assessed by the State Trait Anxiety Inventory (STAI)
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in anxiety measured with State Trait Anxiety Inventory.
This is a 40-item questionnaire scored on a 4 point likert scale (1-4).
Overall score ranges from 40 to 160 with higher scores representing greater anxiety.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in Sleep Medication Dose
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in dose of sleep medication.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in Sleep Medication Frequency
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in frequency of sleep medication.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in absolute power on EEG
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Measurement of brainwave activity (absolute power in microvolts) in each frequency band (alpha, beta, theta, delta, gamma) on Quantitative EEG (qEEG).
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in peak amplitude frequency on EEG
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Measurement of brainwave activity (peak amplitude frequency in hertz) in each frequency band (alpha, beta, theta, delta, gamma) on qEEG.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in EEG absolute power z-scores
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Comparison of z-scores for absolute power in each of the frequency bands (alpha, beta, theta, delta, gamma) pre- and post-interventions.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in EEG peak amplitude frequency z-scores
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Comparison of z-scores for peak amplitude frequency in each of the frequency bands (alpha, beta, theta, delta, gamma) pre- and post-interventions.
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Change in EEG coherence z-scores
Time Frame: Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Comparison of z-scores for coherence between EEG sites in each of the frequency bands (alpha, beta, theta, delta, gamma).
|
Baseline, 1 week following each intervention period and 8 weeks following both intervention periods
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Argye E Hillis, MD, MA, Johns Hopkins School of Medicine
Publications and helpful links
General Publications
- Banerjee S, Argaez C. Neurofeedback and Biofeedback for Mood and Anxiety Disorders: A Review of Clinical Effectiveness and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Nov 13. Available from http://www.ncbi.nlm.nih.gov/books/NBK531603/
- Berube S, Nonnemacher J, Demsky C, Glenn S, Saxena S, Wright A, Tippett DC, Hillis AE. Stealing Cookies in the Twenty-First Century: Measures of Spoken Narrative in Healthy Versus Speakers With Aphasia. Am J Speech Lang Pathol. 2019 Mar 11;28(1S):321-329. doi: 10.1044/2018_AJSLP-17-0131.
- Collura, T. (2014). Technical foundations of neurofeedback. New York: Taylor and Francis.
- Fuchs T, Birbaumer N, Lutzenberger W, Gruzelier JH, Kaiser J. Neurofeedback treatment for attention-deficit/hyperactivity disorder in children: a comparison with methylphenidate. Appl Psychophysiol Biofeedback. 2003 Mar;28(1):1-12. doi: 10.1023/a:1022353731579.
- Hetkamp M, Bender J, Rheindorf N, Kowalski A, Lindner M, Knispel S, Beckmann M, Tagay S, Teufel M. A Systematic Review of the Effect of Neurofeedback in Cancer Patients. Integr Cancer Ther. 2019 Jan-Dec;18:1534735419832361. doi: 10.1177/1534735419832361.
- Nan W, Dias APB, Rosa AC. Neurofeedback Training for Cognitive and Motor Function Rehabilitation in Chronic Stroke: Two Case Reports. Front Neurol. 2019 Jul 24;10:800. doi: 10.3389/fneur.2019.00800. eCollection 2019.
- Wang SY, Lin IM, Fan SY, Tsai YC, Yen CF, Yeh YC, Huang MF, Lee Y, Chiu NM, Hung CF, Wang PW, Liu TL, Lin HC. The effects of alpha asymmetry and high-beta down-training neurofeedback for patients with the major depressive disorder and anxiety symptoms. J Affect Disord. 2019 Oct 1;257:287-296. doi: 10.1016/j.jad.2019.07.026. Epub 2019 Jul 5.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Neurocognitive Disorders
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Dementia
- Language Disorders
- Communication Disorders
- Speech Disorders
- Frontotemporal Lobar Degeneration
- Aphasia
- Frontotemporal Dementia
- Aphasia, Primary Progressive
- Pick Disease of the Brain
Other Study ID Numbers
- IRB00242136
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
Clinical Trials on EEG Neurofeedback
-
Radboud University Medical CenterCompleted
-
University of North Carolina, WilmingtonCompleted
-
Tel-Aviv Sourasky Medical CenterUnknownDepression | Premenstrual Dysphoric Disorder (PMDD)Israel
-
Steinn SteingrimssonRecruiting
-
Tel-Aviv Sourasky Medical CenterUnknownDepression | StressIsrael
-
Shahid Beheshti University of Medical SciencesCompletedGeneralized Anxiety DisorderIran, Islamic Republic of
-
Centre Hospitalier Universitaire de BesanconPlateforme NeuraxessRecruitingEmotional Regulation | Risk-TakingFrance
-
University of ConnecticutUnknown
-
Rennes University HospitalUnknown
-
Wyss Center for Bio and NeuroengineeringEcole Polytechnique Fédérale de LausanneCompleted